Cancer stem cell markers in glioblastoma - an update

Eur Rev Med Pharmacol Sci. 2017 Jul;21(14):3207-3211.


The glioblastoma includes brain tumors, which are very aggressive in nature and are among the most common brain tumors in adults. Latest therapeutic avenues involve combination approach. However, the observed median survival is still no more than 15 months. Moreover, there is a scarcity of accurate pre-clinical model systems, which in turn resulted in limited treatment options for this disease. Cancer stem cells are attractive avenues in anticancer research against glioblastoma. Most of the recent studies are focused towards the identification of novel markers for cancer stem cells. The present review article is focused on two important markers in current research viz. Prominin-1 and NPM1 in glioblastoma.

Publication types

  • Review

MeSH terms

  • AC133 Antigen / metabolism
  • Biomarkers, Tumor / metabolism*
  • Brain Neoplasms / diagnosis*
  • Brain Neoplasms / pathology
  • Glioblastoma / diagnosis*
  • Glioblastoma / pathology
  • Humans
  • Neoplastic Stem Cells / metabolism*
  • Neoplastic Stem Cells / pathology
  • Nuclear Proteins / metabolism
  • Nucleophosmin


  • AC133 Antigen
  • Biomarkers, Tumor
  • NPM1 protein, human
  • Nuclear Proteins
  • Nucleophosmin